Home > Publications database > Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial. > print

001     296217
005     20250819095640.0
024 7 _ |a 10.1200/JCO-24-01441
|2 doi
024 7 _ |a pmid:39805062
|2 pmid
024 7 _ |a 0732-183X
|2 ISSN
024 7 _ |a 1527-7755
|2 ISSN
024 7 _ |a altmetric:172983007
|2 altmetric
037 _ _ |a DKFZ-2025-00130
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schouten, Aniek E M
|0 0000-0001-8860-3823
|b 0
245 _ _ |a Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.
260 _ _ |a Alexandria, Va.
|c 2025
|b American Society of Clinical Oncology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755590173_6399
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Apr 10;43(11):1325-1336
520 _ _ |a To evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and is currently lacking.A cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia. Patients with mBC (N = 357) were randomly assigned to either a 9-month, twice-weekly, supervised exercise group (EG) or control group (CG). Costs of the exercise program were calculated through a bottom-up approach. Other health care resource use, productivity losses, and quality of life were collected using country-adapted, self-reported questionnaires. Analyses were conducted from a societal perspective with a time horizon of 9 months. Costs were collected and reported in 2021 Euros (€1 = $1.18 US dollars).Compared with the CG, EG resulted in a quality-adjusted life-year (QALY) gain of 0.013 (95% CI, -0.02 to 0.05) over a 9-month period. The mean costs of the exercise program were €1,696 per patient with one-on-one supervision (scenario 1) and €609 with one-on-four supervision (scenario 2). These costs were offset by savings in health care and productivity costs, resulting in mean total cost differences of -€163 (scenario 1) and -€1,249 (scenario 2) in favor of EG. The probability of supervised exercise being cost-effective was 65% in scenario 1 and 91% in scenario 2 at a willingness-to-pay threshold of €20,000 per QALY.Exercise for patients with mBC increases quality of life, decreases costs, and is likely to be cost-effective. Group-based supervision is expected to have even higher cost-savings. Our positive findings can inform reimbursement of supervised exercise interventions for patients with mBC.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Hiensch, Anouk E
|0 0000-0002-6216-2609
|b 1
700 1 _ |a Frederix, Geert W J
|b 2
700 1 _ |a Monninkhof, Evelyn M
|0 0000-0002-6641-7605
|b 3
700 1 _ |a Schmidt, Martina
|0 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
|b 4
|u dkfz
700 1 _ |a Clauss, Dorothea
|b 5
700 1 _ |a Gunasekara, Nadira
|b 6
700 1 _ |a Belloso, Jon
|b 7
700 1 _ |a Trevaskis, Mark
|0 0000-0002-9078-0180
|b 8
700 1 _ |a Rundqvist, Helene
|0 0000-0002-5617-9076
|b 9
700 1 _ |a Wiskemann, Joachim
|0 P:(DE-He78)60b584aeef81e4c57fd111fa63779b73
|b 10
|u dkfz
700 1 _ |a Müller, Jana
|b 11
700 1 _ |a Sweegers, Maike G
|b 12
700 1 _ |a Fremd, Carlo
|b 13
700 1 _ |a Altena, Renske
|0 0000-0001-6944-5209
|b 14
700 1 _ |a Bijlsma, Rhodé M
|0 0000-0003-0980-6652
|b 15
700 1 _ |a Sonke, Gabe
|0 0000-0001-8088-9628
|b 16
700 1 _ |a Lahuerta, Ainhara
|b 17
700 1 _ |a Mann, G Bruce
|0 0000-0002-2508-9203
|b 18
700 1 _ |a Francis, Prudence A
|0 0000-0002-7207-9286
|b 19
700 1 _ |a Richardson, Gary
|0 0000-0003-2122-8285
|b 20
700 1 _ |a Malter, Wolfram
|0 0000-0002-5693-3120
|b 21
700 1 _ |a Kufel-Grabowska, Joanna
|b 22
700 1 _ |a van der Wall, Elsken
|0 0000-0003-2568-6937
|b 23
700 1 _ |a Aaronson, Neil K
|0 0000-0003-2574-4850
|b 24
700 1 _ |a Senkus, Elzbieta
|b 25
700 1 _ |a Urruticoechea, Ander
|0 0000-0003-0359-3641
|b 26
700 1 _ |a Zopf, Eva M
|b 27
700 1 _ |a Bloch, Wilhelm
|b 28
700 1 _ |a Stuiver, Martijn M
|0 0000-0002-7794-7767
|b 29
700 1 _ |a Wengstrom, Yvonne
|b 30
700 1 _ |a Steindorf, Karen
|0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
|b 31
|u dkfz
700 1 _ |a van der Meulen, Miriam P
|b 32
700 1 _ |a May, Anne M
|0 0000-0003-0643-3790
|b 33
773 _ _ |a 10.1200/JCO-24-01441
|g p. JCO-24-01441
|0 PERI:(DE-600)2005181-5
|n 11
|p 1325-1336
|t Journal of clinical oncology
|v 43
|y 2025
|x 0732-183X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:296217
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)60b584aeef81e4c57fd111fa63779b73
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN ONCOL : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a IF >= 40
|0 StatID:(DE-HGF)9940
|2 StatID
|b J CLIN ONCOL : 2022
|d 2023-10-22
920 1 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Krebsprävention und Survivorship
|x 0
920 1 _ |0 I:(DE-He78)D120-20160331
|k D120
|l Angewandte Tumor-Immunität
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C110-20160331
980 _ _ |a I:(DE-He78)D120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21